‘Chemobrain’: Cognitive Impairment May Be a Form Of Cancer-Related PTSD

Dr. Kerstin Hermelink Senior psychologist  Dept. of Gynecology and Obstetrics Ludwig Maximilian University of MunichMedicalResearch.com Interview with:
Dr. Kerstin Hermelink
Senior psychologist
Dept. of Gynecology and Obstetrics
Ludwig Maximilian University of Munich

MedicalResearch: What is the background for this study? What are the main findings?

Dr. Hermelink: Many breast cancer patients report problems of cognitive functioning that interfere considerably with their professional and private lives. In the last two decades, a number of studies have confirmed that subgroups of breast cancer patients show at least subtle cognitive impairment. Initially, the condition has entirely been attributed to chemotherapy effects and has therefore colloquially been named “chemobrain”. Meanwhile, however, cognitive impairment has also been found in patients who were managed without chemotherapy and, surprisingly, even in patients who had not yet received any systemic treatment at all.

Several hypotheses on the causation of cognitive impairment that occurs already pretreatment have been put forward; for instance, biological effects of the cancer itself might affect cognitive functioning, or there might be shared genetic vulnerability for cancer and cognitive impairment. None of these hypotheses have been empirically confirmed; thus, pretreatment cognitive impairment is as yet unexplained.

Our study was designed to investigate the effects of cancer-related post-traumatic stress on cognitive function in breast cancer patients before the start of treatment. Stress has a substantial influence on cognitive functioning, and post-traumatic stress disorder (PTSD) is associated with impairment of cognitive function. While the incidence of full diagnosis of stress disorder is low among breast cancer patients, many of these patients show symptoms of PTSD, with a peak shortly after diagnosis.

We did not find an elevated risk of overall cognitive impairment in pretreatment breast cancer patients compared with matched non-cancer controls; however, the cancer patients scored worse than the controls on a small fraction of the cognitive indices that were used. Performance on these indices was indeed robustly associated with PTSD symptoms.

Our results therefore indicate that pretreatment cognitive impairment in breast cancer patients may be largely caused by the stress of being diagnosed with cancer.

MedicalResearch: What should clinicians and patients take away from your report?

Dr. Hermelink: Clearly, our findings are good news for breast cancer patients. If cognitive impairment is caused by post-traumatic stress, there is reasonable hope that it can be efficiently treated. Clinicians should be aware that complaints of cognitive impairment may be related to cancer-related post-traumatic stress, and they should consider psycho-oncologic intervention.

MedicalResearch: What recommendations do you have for future research as a result of this study?

Dr. Hermelink: In studies of cancer-related cognitive impairment, psychological factors have as yet mainly been regarded as confounders. Apparently, more attention should be given to the contribution of these factors. In particular, the effects of cancer-related stress on cognitive function and on the brain should be investigated in hypothesis-driven studies.

Citation:

Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-related Post-traumatic Stress

Kerstin Hermelink, Varinka Voigt, Judith Kaste, Franziska Neufeld, Rachel Wuerstlein, Markus Bühner, Karin Münzel, Dorothea Rjosk-Dendorfer, Susanne Grandl, Michael Braun, Franz Edler von Koch, Kristin Härtl, Stephan Hasmüller, Ingo Bauerfeind, Gerlinde Debus, Peter Herschbach, and Nadia Harbeck

JNCI J Natl Cancer Inst (2015) 107 (7): djv099 doi:10.1093/jnci/djv099

kerstin.hermelink@med.uni-muenchen.de